Results 21 to 30 of about 60,909 (346)

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source

Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy

European Journal of Heart Failure, 2023
Transthyretin amyloid cardiomyopathy (ATTR‐CM) is often assumed to be associated with wild‐type TTR genotype (ATTRwt) in elderly patients (aged ≥70), some of whom are not offered genetic testing.
A. Porcari, Y. Razvi, A. Masi, R. Patel, A. Ioannou, M. Rauf, D. Hutt, D. Rowczenio, J. Gilbertson, A. Martinez-Naharro, L. Venneri, C. Whelan, H. Lachmann, A. Wechalekar, C. Quarta, M. Merlo, G. Sinagra, P. Hawkins, M. Fontana, J. D. Gillmore   +19 more
semanticscholar   +1 more source

RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis

BioDrugs, 2023
Transthyretin (TTR) is a tetrameric protein synthesized primarily by the liver. TTR can misfold into pathogenic ATTR amyloid fibrils that deposit in the nerves and heart, causing a progressive and debilitating polyneuropathy (PN) and life-threatening ...
A. Ioannou, M. Fontana, J. Gillmore
semanticscholar   +1 more source

Comparative Stability and Clearance of [Met30]Transthyretin and [Met119]Transthyretin [PDF]

European Journal of Biochemistry, 1997
[Met119]Transthyretin has been described as a non‐amyloidogenic transthyretin variant. In Portugal, it has also been found in compound heterozygotic individual carriers of [Met30]transthyretin, the most prevalent variant associated with familial amyloidotic polyneuropathy.
Isabel Alves, Maria João Saraiva, Marguerite T. Hays   +2 more
openaire   +3 more sources

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Global Heart, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment.
Dulce Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, Nicole Bart, Nathan Better, I. Carvajal-Juárez, I. Conceição, Thibaud Damy, S. Dorbala, Jean-Christophe Fidalgo, P. García-Pavía, Junbo Ge, J. Gillmore, Jacek Grzybowski, L. Obici, Daniel Piñero, Claudio Rapezzi, Mitsuharu Ueda, Fausto J. Pinto   +18 more
semanticscholar   +1 more source

Placental transfer of a hydroxylated polychlorinated biphenyl and effects on fetal and maternal thyroid hormone homeostasis in the rat [PDF]

, 2002
Earlier studies at our laboratory indicated that several hydroxylated polychlorinated biphenyls (OH-PCBs) detected in human blood could specifically inhibit thyroxine (T4) transport by competitive binding to the thyroid hormone transport protein ...
Assink, Y., Berg, J.H.J. van den, Bergman, A., Brouwer, A., Cenijn, P.H., Koeman, J.H., Meerts, I.A.T.M., Weijers, B.M.   +7 more
core   +7 more sources

Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy

Frontiers in Neurology, 2023
Amyloidoses represent a group of diseases characterized by the pathological accumulation in the extracellular area of insoluble misfolded protein material called “amyloid”.
L. Poli, Beatrice Labella, S. Cotti Piccinelli, F. Caria, B. Risi, Simona Damioli, Alessandro Padovani, M. Filosto   +7 more
semanticscholar   +1 more source

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Orphanet Journal of Rare Diseases, 2023
Background Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, multisystemic, life-threatening disease resulting from the deposition of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in various tissues and organs ...
L. Gentile, Teresa Coelho, A. Dispenzieri, I. Conceição, M. Waddington-Cruz, A. Kristen, J. Wixner, Igor Diemberger, J. González-Moreno, E. Cariou, M. S. Maurer, V. Planté-Bordeneuve, P. García-Pavía, I. Tournev, J. González-Costello, Alejandra Gonzalez Duarte, M. Grogan, Anna Mazzeo, Doug Chapman, Pritam Gupta, Oliver Glass, L. Amass   +21 more
semanticscholar   +1 more source

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

European Journal of Heart Failure, 2023
The value of disease‐modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) and severe heart failure symptoms has been debated.
P. Elliott, B. Gundapaneni, M. Sultan, M. Inês, P. García-Pavía   +4 more
semanticscholar   +1 more source